0000911916-16-000693.txt : 20161201
0000911916-16-000693.hdr.sgml : 20161201
20161201164356
ACCESSION NUMBER: 0000911916-16-000693
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161201
FILED AS OF DATE: 20161201
DATE AS OF CHANGE: 20161201
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CoLucid Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348649
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203419541
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 781-365-2596
MAIL ADDRESS:
STREET 1: 222 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Colucid Pharmaceuticals Inc
DATE OF NAME CHANGE: 20060104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dallas Matthew D
CENTRAL INDEX KEY: 0001612396
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37358
FILM NUMBER: 162028843
MAIL ADDRESS:
STREET 1: AVEO PHARMACEUTICALS, INC.
STREET 2: 650 EAST KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2016-12-01
0001348649
CoLucid Pharmaceuticals, Inc.
CLCD
0001612396
Dallas Matthew D
C/O COLUCID PHARMACEUTICALS, INC.
222 THIRD STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Financial Officer
Common Stock
2016-12-01
4
S
0
1473
35.1671
D
41601
D
Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.
Represents the sale of 1,473 shares in multiple transactions, ranging in price from $35.00 to $35.45 per share, resulting in a weighted average sale price of $35.1671. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
Includes 5,574 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016.
/s/ Christine G. Long, Attorney-in-Fact for Matthew D. Dallas (power of attorney previously filed)
2016-12-01